Methods of device-assisted drug delivery

An active ingredient, a vasodilator technology, applied in the field of transdermal drug delivery, can solve problems such as limited capacity, and achieve the effects of increased speed, increased flexibility, improved efficiency and kinetics

Inactive Publication Date: 2007-08-22
BIOCHEMICS
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the capabilities of these systems are limited due to the significant barriers presented by the stratum corneum to achieve successful transdermal drug delivery with or without the use of vasoactive chemicals.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion (Lipomulse) 165 (2%) and cetyl alcohol (2%) at 40°C Stir for 30 minutes and mix well. Another container contained acrylic acid polymer (Pemulen) (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed at room temperature for about 20 minutes until homogeneous. 100 μg of recombinant human growth hormone was dissolved in (1%) physiological saline. Add somatotropin to the primary delivery vehicle formulation and mix well. A 1 g aliquot was taken into a container in a 1 cc 29 gauge injection needle device and injected into the subcutaneous tissue to be delivered.

Embodiment 2

[0028] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion 165 (2%) and cetyl alcohol (2%) were stirred at 40°C for 30 minutes and mix well. Another container contained acrylic acid polymer (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed for about 20 minutes at room temperature until homogeneous. 100 μg of recombinant human growth hormone was dissolved in (1%) physiological saline. Add somatotropin to the primary delivery vehicle formulation and mix well. Aliquots of 1 g are added to containers in microneedle devices designed to deliver substances in precise quantities. The device is brought into contact with the skin, and the pharmaceutical composition and the vasoactive drug delivery formulation carrier are administered simultaneou...

Embodiment 3

[0030] Oleic acid (5%), γ-linolenic acid (5%), cholesterol (1%), menthol (5%), fat emulsion 165 (2%) and cetyl alcohol (2%) were stirred at 40°C for 30 minutes and mix well. Another container contained acrylic acid polymer (1%) and propylene glycol (10%), mixed well and then added to the first container to form an emulsion. A third mixture consisting of tolazoline (1%), papaverine (0.5%) was added to (5%) propylene glycol and (56.5%) deionized water. The mixture was then mixed for about 20 minutes at room temperature until homogeneous. A separate formulation of the active drug molecule (eg 0.1% human insulin) is prepared, dissolved in (1%) saline and added to the drug delivery formulation in a separate and separate container in the delivery device. The drug formulations (0.1-2 g of each dosing vehicle) are applied to the reservoir of a microneedle device designed to deliver substances in precise quantities. The device is brought into contact with the skin, and the pharmaceu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention describes the simultaneous or sequential administration of therapeutic or diagnostic agents using different devices in combination with a chemical formulation that incorporates or uses vasomodulatory chemical agents as part of the drug delivery vehicle. Methods include the addition of various vasodilatory and vasoconstrictive agents to enhance the systemic or localized tissue delivery of therapeutic or diagnostic agents delivered into a body through the use of an apparatus or device.

Description

field of invention [0001] The present invention relates to transdermal administration of therapeutic or diagnostic substances with devices or devices to assist in the delivery process, including iontophoresis, sonophoresis, syringes and injection needles, and microneedle devices. The present invention specifically describes the enhanced drug delivery properties when these agents are formulated with vasomodulating chemicals to induce a vasodilation or vasoconstriction response in the tissue area subjected to the drug, such as the injection site. Background of the invention [0002] Systemic or topical delivery of drugs has been performed for many years by dermal administration using syringes and needles. However, the physical action of the needle penetrating the skin has certain significant negative reactions, including pain and discomfort, and potential adverse reactions to local tissues due to the trauma of physical disruption caused by relatively large needles penetrating ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61F13/00
CPCA61K9/0021
Inventor S·G·卡特Z·朱K·帕特尔
Owner BIOCHEMICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap